Purpose: Current cataract surgery guidelines recommend routine use of topical nonsteroidal anti-inflammatory drugs (NSAIDs) in preventing pseudophakic cystoid macular oedema (PCME). Here, we compare the clinical efficacy and tolerability of two potent NSAIDs, nepafenac and preservative-free diclofenac following cataract surgery. Methods: Randomized, double-blind, prospective single-centre study. Ninety-six eyes of 95 patients undergoing routine cataract surgery were randomized 1:1 either to nepafenac (Nevanac, 1 mg/ml) or diclofenac (Dicloabak, 1 mg/ml) for 3 weeks. Seventy-three patients accounting for 73 eyes completed the entire follow-up. Aqueous flare and central retinal thickness (CRT) analysis were conducted preoperatively and at control visits 28 days and 3 months after surgery. A structured home questionnaire and interview were used to record any adverse effects of the topical medications, subjective visual recovery and the dispenser's ease of use. Results: No differences were observed between the groups for aqueous flare, CRT, speed of recovery or visual acuity gain. Seven patients (16%) on nepafenac and 20 patients (48%) on preservative-free diclofenac reported symptoms related to topical use of NSAID medications (p = 0.001). Conclusion: No differences in clinical efficacy were found between potent NSAIDs, while tolerability might be an issue.
Introduction
With modern surgical techniques, the frequency of complications following cataract surgery has reduced significantly. However, complications are still a substantial burden because of the sheer number of cataract surgeries performed worldwide each year. Preand postsurgical medical interventions with topical anti-inflammatory drugs are employed to minimize postoperative inflammation and the risk of developing pseudophakic cystoid macular oedema (PCME; Donnenfeld et al. 2006; Yavas et al. 2007; Kim et al. 2010; Kessel et al. 2014; Wielders et al. 2015) . Other points of interest when comparing different topical drugs have been the speed of visual recovery and drug tolerability (Maca et al. 2010; Duong et al. 2014; Kessel et al. 2014; Coassin et al. 2016; Ba-Ali et al. 2017) . In clinical practice, the treatment protocol for normal and high-risk patients regarding PCME is currently shifting from topical steroid use to either application of nonsteroidal anti-inflammatory drug (NSAID) medication or a combination of both types of medication (Kessel et al. 2014; Wielders et al. 2015; Margulis et al. 2017) . Different NSAID eye drops have been tested against steroids, but there have not been enough head-to-head comparisons between NSAIDs to recommend one over another (Kessel et al. 2014; Sahu et al. 2015; Achiron et al. 2016) .
The tolerability of nepafenac and diclofenac has proven to be similar (Achiron et al. 2016) . Previous studies have shown preservative-free diclofenac to have better tolerability and cause less ocular discomfort than the preserved version (Maca et al. 2010) . We hypothesize that, of the two commonly prescribed NSAIDs, preservative-free diclofenac will be better tolerated than nepafenac.
To our knowledge, the efficacy of these drugs as part of the postcataract removal treatment regimen has not been compared, making a study to measure aqueous flare, central retinal thickness (CRT) and tolerability warranted.
Materials and Methods

Study design
This study was conducted as a randomized, double-blind, prospective singlecentre study. Patients were admitted as per the national guidelines for the management of cataract in the Department of Ophthalmology, Kymenlaakso Central Hospital, Kotka, Finland. A total of 96 eyes for either nepafenac (Nevanac Ò , nepafenac 1 mg/ml; Novartis, Basel, Switzerland), or preservative-free diclofenac (Dicloabak Ò , diclofenac sodium 1 mg/ml; Laboratoires Th ea, ClermontFerrand, France) eye drops. Both antiinflammatory eye drops were used three times a day (t.i.d.) for 21 days. No preoperative use of these eye drops or tapering down schedule was used.
The patients were examined preoperatively by an ophthalmologist on the day of the surgery, and they visited research technician 28 days after the operation (AE2 days; Eloranta & Falck 2017) . A second postoperative visit to the research technician was scheduled for 3 months after the surgery. On each visit, aqueous flare and mean CRT were recorded by a laser flare meter (FM-600; Kowa Company, Ltd., Nagoya, Japan) and spectral-domain optical coherence tomography (SD-OCT, Heidelberg Eye Explorer Version 1.9.10.0 and HRA/ SPECTRALIS Ò Viewing Module Version 6.0.9.0; Heidelberg Engineering GmbH, Heidelberg, Germany).
A structured take-home questionnaire and interview were used to record subjective drug-related symptoms and recovery from the surgery.
The study was conducted according to the tenets of the Declaration of Helsinki and was approved by the Finnish Medicines Agency Fimea and the Institutional Review Board of Helsinki University Hospital (EudraCT Number: 2015-005313-79) . A written consent was obtained from each participant before enrolment in the study. Patient records were kept confidential when the clinical data were entered into a standardized database for analysis.
Patients
A total of 96 eyes of 95 patients scheduled for cataract surgery were enrolled between October 2016 and December 2016. Baseline variables were evaluated according to intentionto-treat analysis (Table 1) .
Before their 28-day control visits, four patients decided not to continue as part of the study (Fig. 1) . They either gave no specific reasons or could not attend the scheduled control visit (three patients in the nepafenac group and one patient in the diclofenac group). Moreover, five patients were excluded from the study (Fig. 1) . Two patients were excluded because of medication intolerance, and one patient because of developing exudative age-related macular degeneration (AMD) by the 28-day control visit. Moreover, two patients were unable to correctly administer the eye drops from the dispenser and were therefore removed from the study.
Between their 28-day and 3-month postoperative visits, six patients in the nepafenac group and eight patients in the diclofenac group either withdrew from the study or otherwise failed to attend the second visit. After these participants dropped out, a total of 87 eyes of 87 patients remained for inclusion in the analysis at the 28-day postoperative visit, and a total of 73 eyes of 73 patients (39 nepafenac, 34 diclofenac) remained at the 3-month postoperative visit (Fig. 1 ).
Inclusion criteria
The study subjects were aged 60-90 years and were eligible for cataract surgery under the Current Care Guidelines of Cataract Surgery of the Finnish Medical Society, Duodecim (updated in 2013).
Exclusion criteria
Exclusion criteria for the study included prior or active wet AMD or ocular pathologies including retinal vein/artery occlusion, retinal detachment or optic neuritis, previous intraocular procedures (including fundus laserphotocoagulation), scheduled anti-vascular endothelial growth factor (anti-VEGF) treatment and myopia above À6.0 diopters. Alcohol abuse, thyroid disease with abnormal thyroidstimulating hormone (TSH) levels, continuous use of anti-inflammatory drugs and sensitivity to any of the medications used during or after the operation were also considered as exclusion criteria. Criteria for exclusion were also intraoperative complications such as iris prolapse, use of sutures or posterior capsule tear, failure to attend the postoperative control visit at 28 AE 2 days or 3 months AE 7 days and failure to use the postoperative anti-inflammatory medication as prescribed.
Randomization
The study was conducted as a randomized, double-blind, prospective singlecentre study (hrrg.fi/en/clinicaltrials/ cataract/). The patients were randomized into two groups prescribed different postoperative anti-inflammatory medications: (i) nepafenac eye drops three times a day (t.i.d.) for 3 weeks; (ii) preservative-free diclofenac eye drops t.i.d. for 3 weeks. No antiinflammatory drops were used preoperatively.
The drug labels were covered with our hospital pharmacy's labels, and the bottles were then put into marked envelopes. The research technician randomized patients after their cataract surgeries and then distributed the marked envelopes accordingly. The drugs were unblinded after the data were analysed.
Structured home questionnaire
On surgery day, patients received a structured take-home questionnaire. Structured home questionnaires were crosschecked by the patient and research technician at the 28-day postoperative visit, before collecting data. The regularity of eye drop use, adverse effects of topical medication, duration of conjunctival injection and/or eye irritation, medicine dispenser's ease of use and the participants' subjective visual recovery were recorded. Overall satisfaction was recorded by an interview by a research technician at the 28-day postoperative visit.
Surgery
A standardized phacoemulsification technique was used for all cataract surgeries (hrrg.fi/en/videos/cataract/), as described in (Ylinen et al. 2018 ).
The surgeries were performed by a group of two ophthalmology residents and three specialists.
Clinical evaluation
Biometry [using swept-source optical coherence tomography (SSOCT) technology], aqueous flare (using automated laser flare metering technology), best corrected visual acuity (BCVA) and intraocular pressure (IOP) were evaluated as described in our earlier report (Ylinen et al. 2018 ). The change in CRT was measured with SD-OCT (Heidelberg Engineering GmbH). The diagnosis of PCME was based on typical OCT findings with cystoid macular oedema and clinical evaluation (Kim et al. 2007; Kusbeci et al. 2012; Singh et al. 2012; Pollack et al. 2017) . When PCME was diagnosed, topical NSAID (nepafenac 1 mg/ ml, three times a day) was prescribed for 3 months. Intravitreal dexamethasone implantation was recommended for PCMEs which did not respond to 3 months of NSAID. Pseudophakic cystoid macular oedema and its treatment were not exclusion criteria.
Power analysis
The power analysis was based on sample size estimates for subjective irritation symptoms. The proportion of patients with no subjective irritation symptoms caused by the eye drops was estimated at 0.65 for the nepafenac group and 0.8 for the diclofenac group. The non-inferiority margin was set at 0.1, with 80% power and sampling ratio of 1:1. The sample size estimation was 39 on each group. With 20% estimated dropout rate, the final sample size estimate was 49 on each group.
Statistical analyses
Data are given as mean AE SEM, except for the absolute numbers and proportions for the nominal scale. Statistical analysis was completed using IBM SPSS Statistics 24 (SPSS Inc., Somers, NY, USA). Data were analysed with Student's t-test for normally distributed continuous variables and the Mann-Whitney U-test for nonparametric variables at a given timepoint. Change in aqueous flare, CRT, IOP and BCVA was analysed with a repeated-measures ANOVA test. Categorical data were analysed with the two-factor v² test, or with Fisher's exact test when values in any of the cells of a contingency table were below five. Best corrected visual acuity decimal values were converted to logarithm of the minimum angle of resolution (logMAR) for statistical purposes. A linear regression model was used to estimate the relationships between variables. p ≤ 0.05 was considered statistically significant.
Results
Baseline variables
Baseline variables regarding (i) patient (gender, age, diabetes), (ii) ophthalmic [aqueous flare, CRT, IOP, BCVA, Clinical efficacies according to aqueous flare and CRT were comparable between nepafenac and diclofenac at 28 days and 3 months (Table 2) . Moreover, IOP and BCVA were comparable between the groups at each timepoint (Table 2) .
In diabetic and non-diabetic patients, aqueous flare at 28 days (12.1 AE 2.4 pu/msec versus 10.5 AE 0.8 pu/msec, p = 0.434) and at 3 months (7.9 AE 1.0 pu/msec versus 9.1 AE 0.7 pu/msec, p = 0.496) were comparable. There was also no difference in CRT at 28 days (287.6 AE 11.0 lm versus 278.0 AE 4.0 lm, p = 0.327) and at 3 months (281.4 AE 6.7 lm versus 281.1 AE 4.9 lm, p = 0.971).
Subjective symptoms from NSAID eye drops
Subjective symptoms and visual recovery were documented in the structured home questionnaire, which was collected by the research technician at the 28-day postoperative visit. A total of 27 of 87 study eyes (31%) were reported as showing NSAID eye drop-related symptoms. Seventeen (63%) patients reported a stinging/ burning sensation, five (19%) were unable to specify the symptom, three patients from the diclofenac group described itching, one in the nepafenac group described itching with stinging/ burning, and one in the diclofenac group described a foreign body sensation. In general, the stinging/burning sensation was transient, whereas itching caused greater, more prolonged discomfort.
In the nepafenac group, seven (16%) eyes suffered from drug-related symptoms. In the diclofenac group, twenty (48%) eyes were reported to have drug-related symptoms (p = 0.001, Table 3 ). Of note, the analysis does not include the two diclofenac group patients who were excluded from the study due to medication intolerance (Fig. 1) .
Duration of conjunctival injection and/or irritation of the eye was subjectively evaluated by the patients themselves: 4.6 AE 0.8 days in the nepafenac group, and 4.5 AE 0.8 days in the diclofenac group (p = 0.960, Table 3 ).
The subjective visual acuities of eighty study eyes (92%) were reported as reaching their maximum and stabilizing in a week or less, while four eyes in the nepafenac group and three eyes in the diclofenac reached maximum and stable visual acuity after more than a week or the patients were not able to notice the visual improvement at all (p = 0.765, Table 3 ).
Nine patients (20%) from the nepafenac group and 13 (31%) from the diclofenac group reported having difficulties with the dispenser/administration of the drug (p = 0.240, Table 3 ). Of note, the analysis does not include the two diclofenac group patients who were excluded from the study when, at the 28-day visit, they revealed that they did not administer the drugs at all because they were unable to manage their dispensers (Fig. 1) . In both groups, the most commonly reported issue was the challenge of pressing down hard enough for the dispenser to work.
From the economic viewpoint, for four of the 48 patients (8%) in the nepafenac group, one bottle of eye drops prescribed t.i.d. for 3 weeks was insufficient. However, none of the patients in the diclofenac group used more than one bottle. At the time this article was written, the price (before the National Health Insurance reimbursement for medical expenses) of Nevanac Ò 1 mg/ml (5 ml) was 24,01€ and Dicloabak Ò 1 mg/ml (10 ml) was 11,97€.
Effect of NSAID eye drops on presence of PCME Three cases of PCME were diagnosed during the 3-month follow-up: one after nepafenac and two after diclofenac treatment (p = 0.517).
At 28 days, PCME was diagnosed in one eye from the nepafenac group, but none from the diclofenac group. At 28 days, CRT in the one eye with PCME was 396 lm and change from the baseline was +112 lm. In the other eyes, CRT was 278.1 AE 3.4 lm (change +2.3 AE 1.0 lm). Best corrected visual acuity was 0.20 logMAR units (change from baseline À0.20 logMAR units) in the one PCME eye, compared to 0.07 AE 0.02 logMAR units (change from baseline À0.40 AE 0.03 logMAR units) in eyes without PCME.
At 3 months, PCME was diagnosed in two eyes in the diclofenac group and in none in the nepafenac group. Central retinal thickness was 349.0 AE 12.0 lm (change +78.0 AE 22.0 lm) in the eyes with PCME and 280.4 AE 3.9 lm (+5.0 AE 1.8 lm) in the others. Best corrected visual acuity was 0.35 AE 0.05 logMAR units (change from baseline À0.11 AE 0.01 logMAR units) in the eyes with PCME and 0.05 AE 0.02 log-MAR units (change from baseline À0.41 AE 0.03 logMAR units) in eyes without PCME.
Baseline patient, ophthalmic and surgical parameters such as patient age and gender, diabetes, pseudoexfoliation syndrome, phaco energy, duration of operation and use of pupil expansion device or capsular tension ring (CTR) were not associated with PCME (p = not significant for all, data not shown).
Effect of surgical parameters on the clinical efficacy and tolerability measures
Aqueous flare, CRT, BCVA and IOP at 28 days and 3 months did not correlate with the duration of operation or phacoemulsification energy (p = not significant for all, data not shown). Furthermore, aqueous flare, CRT, BCVA and IOP after surgery were comparable at each visit between eyes with and without subjective drugrelated symptoms (p = not significant for all, data not shown).
In eyes with and without subjective symptoms, the operation time was comparable (20.4 AE 2.5 min in eyes with symptoms and 22.0 AE 0.9 min in eyes without, p = 0.456). However, phacoemulsification energy, reflecting the density of cataract, was lower in eyes with subjective symptoms compared to those without symptoms (16.8 AE 1.8 CDE in eyes with symptoms and 24.3 AE 1.6 CDE in eyes without, p = 0.006).
Furthermore, clinical efficacy and tolerability of the NSAIDs were comparable between the eyes with and without concomitant glaucoma medication (Table S1 ).
Overall patient satisfaction
On a scale of 0-10, the overall patient satisfaction was 9.23 AE 0.18 (range 4-10) in the nepafenac group and 9.53 AE 0.13 (range 6-10) in the diclofenac group (p = 0.175).
The subjective duration of conjunctival injection and/or irritation of the eye was correlated with patient satisfaction (R 2 = 0.207, p < 0.001). Moreover, the length of the surgical procedure inversely correlated with patient satisfaction (R 2 = 0.170, p < 0.001). In the nepafenac group, from among patients with subjective drug-related symptoms, satisfaction was 7.80 AE 1.00, compared to 9.43 AE 0.13 for those without symptoms (p = 0.168). In the diclofenac group, in patients with subjective drug-related symptoms, satisfaction was 9.45 AE 0.22, compared to 9.61 AE 0.14 for those without symptoms (p = 0.546). In patients who experienced difficulty with the dispenser/drug administration, satisfaction was 9.11 AE 0.24, compared to 9.48 AE 0.12 for those who had no trouble (p = 0.141).
Patient satisfaction with residents and specialists in ophthalmology was comparable (p = 0.822, data not shown). Patient satisfaction did not correlate with phacoemulsification energy (R 2 = 0.018, p = 0.235). It did not correlate with the eventual BCVA at 3 months (R 2 < 0.001, p = 0.953), or with the BCVA gain at 3 months either (R 2 = 0.002, p = 0.692). There was no significant difference in satisfaction score among patients with and without PCME (p = 0.516).
Discussion
This study was conducted to make the choice between topical NSAIDs commonly used following cataract operation easier. We aimed to define possible differences in efficacy and tolerability between the two NSAIDs, rather than optimizing the treatment protocols for the use of the drugs. The treatment protocol resembled our current clinical practice of prescribing NSAID monotherapy for a 3-week period following surgery. Other protocols using preoperative treatment, tapering down schedule and those favouring a combination of NSAIDs and steroids also exist (Donnenfeld et al. 2006; Wielders et al. 2015) . The efficacy of these drugs seemed to be comparable, noting similar aqueous flare, CRT measurements and PCME incidence.
Subjective ocular symptoms have been measured using a visual analogue scale (VAS) (Achiron et al. 2016 ; Data are given as mean (AESEM) or absolute number and proportion. For two-group comparisons, qualitative data were analysed with the two-factor v² test. Student's t-test was used for continuous variables. VA; visual acuity. (i) Subjective symptoms were reported as itching with stinging, burning, foreign body sensation. *The analysis does not include those two enrolled patients in the diclofenac group who were excluded due to medication intolerance. (ii) Duration of conjunctival injection and/or irritation of the eye. (iii) The number of patients reporting subjective visual acuity to reach its maximum and remain stable in above 1 week. (iv) Difficulties with the dispenser/administration of the drug. † The analysis does not include those two enrolled patients in the diclofenac group who at 28 days revealed that they were unable to use the dispenser and administer drugs at all and were therefore excluded from the study. Bolded text indicates p ≤ 0.05 was considered statistically significant. Hosseini et al. 2016) . According to VAS analysis, preservative-free diclofenac caused less discomfort, itching, pain and burning sensation than did preserved diclofenac (Moisseiev & Varssano 2011) . Even though VAS presents information on the severity of symptoms, we felt that dichotomous variables are more suitable in this setting as it is highly demanding for the study subjects to define symptom severity. Here, we decided to document adverse effects of topical medication, medicine dispenser's ease of use and the participants' subjective visual recovery with more robust dichotomous variables, which are easier for patients to comprehend. In this study, nepafenac and preservative-free diclofenac were tested for the hypothesis that nepafenac use should result in more frequent subjective drugrelated symptoms than preservative-free diclofenac use. In fact, preservative-free diclofenac has been the primary antiinflammatory drug in our unit, used for approximately 2000 cataract surgeries per year. Surprisingly, the study subjects had significantly fewer subjective irritation symptoms from using nepafenac, leading to the rejection of our hypothesis. Incidence of drug-related symptoms in the study was relatively high compared to clinical experience, but comparable to the findings of our previous report on topical NSAID medication (Ylinen et al. 2018) . When assessing these results, it should be noted that concomitant use of chronic eye drops might affect both the clinical efficacy and tolerability of the studied anti-inflammatory drugs. Glaucoma medication was equally distributed between the groups and, in fact, clinical efficacy and tolerability of the tested NSAIDs were equally good both in eyes with glaucoma medication and in those without medication.
We found that, in patients with subjective drug-related symptoms, operations were completed with lower phacoemulsification power. This may be explained by the differences in subjective benefit from the surgery, as lower levels of phacoemulsification power did correlate with better baseline BCVA. Interestingly, the durations of the surgical procedure and of conjunctival injection/postoperative irritation of the eye correlated with overall satisfaction, whereas parameters, such as drugrelated symptoms, BCVA gain and even presence of PCME, did not. Overall satisfaction might correlate well with other factors, such as severe negative dysphotopsia (Makhotkina et al. 2018 ), and quality of vision which could be measured with questionnaires like Catquest-9SF (Stolk-Vos et al. 2018) .
Some earlier studies comparing the efficacy or tolerability of various NSAIDs have revealed that ketorolac is, subjectively, better appreciated than nepafenac, with no difference in efficacy between the two (Duong et al. 2007) . Ketorolac was also comparable in efficacy to diclofenac, and preservative-free diclofenac was found to be best-tolerated when compared against ketorolac and preserved diclofenac (Flach 1998; Maca et al. 2010) . It was also reported that preservatives may suppress the antiinflammatory efficacy of diclofenac (Yasuda et al. 2012) . Flurbiprofen and indomethacin were less effective than diclofenac (Diestelhorst et al. 1996) . Taken together, our results support the earlier findings that nepafenac and diclofenac are comparable in efficacy, and that the choice between them should be made based on other factors, such as tolerability, availability and price.
Preference is shifting towards NSAIDs instead of steroids for treating postcataract removal inflammation (Kessel et al. 2014; Wielders et al. 2015; Ylinen et al. 2018) . The choice between various NSAIDs has not been backed by sufficient clinical experiments (Kessel et al. 2014) . Our data seem to favour nepafenac over preservative-free diclofenac when considering tolerability. As there are various protocols with NSAIDs for their preoperative use and combination with steroids, this subject requires additional studies to define optimized treatment.
